Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid Antagonism in Hypogonadotropic Hypogonadism
NCT04975334Phase 1Completed
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naloxone in hypogonadotropic hypogonadism (HH). Primary endpoint: Average Change in Mean Luteinizing Hormone (LH) Value at 3 hours. Started Jun 2025; status: completed.
02
Drugs
naloxone
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT04975334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975334.